EP1317450B1 — Pyrazole compounds useful as protein kinase inhibitors
Assigned to Vertex Pharmaceuticals Inc · Expires 2006-11-22 · 19y expired
What this patent protects
This invention describes novel pyrazole compounds of formula III:wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R?x and Ry¿ are taken together with their intervening atoms to form a fuse…
USPTO Abstract
This invention describes novel pyrazole compounds of formula III:wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R?x and Ry¿ are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered carbocyclo ring; and R?2 and R2'¿ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Drugs covered by this patent
- Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.